Non-alcoholic fatty liver disease (NAFLD) is a complex spectrum of liver diseases with risk factors almost identical to those of metabolic syndrome i.e. obesity, diabetes, hyperlipidaemia and hypertension. An initial accumulation of lipid in the liver results in simple hepatic steatosis, a relatively benign condition. However, if lipids continue to accumulate and the liver becomes inflamed the disease can progress onto non-alcoholic steatohepatitis (NASH) and fibrosis which can lead to cirrhosis, hepatocellular carcinoma (HCC) and ultimately end-stage liver disease. Due to the propensity for NASH and fibrosis to progress to end-stage liver disease, with few treatment options available, there is a high level of need to identify drug therapies to correct the underlying metabolic deficits, and to prevent or alleviate hepatic fibrosis and NASH.
RenaSci offer a range of in vivo models of NAFLD, these include DIO rat and mouse models of simple hepatic steatosis and nutrient-deficient diet (CD) and genetically obese ob/ob high-fat, high-fructose, high- cholesterol diet (ob/ob H-FFC) mouse models of NASH and fibrosis. RenaSci can also measure liver function and pathology through a range of assays either as part of an in vivo project or as standalone analysis.
For more details or information on how we can support your project please complete the contact form.